TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease
- 1 December 2005
- journal article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 37 (12) , 940-945
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Review article: monitoring of immunomodulators in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2005
- Mutation in theITPAGene Predicts Intolerance to AzathioprineNucleosides, Nucleotides & Nucleic Acids, 2004
- Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid‐dependent ulcerative colitisAlimentary Pharmacology & Therapeutics, 2004
- Drug methylation in cancer therapy: lessons from the TPMT polymorphismOncogene, 2003
- Thiopurine S‐methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2003
- Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2002
- Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel diseaseGut, 2001
- METHYLATION PHARMACOGENETICS: Catechol O-Methyltransferase, Thiopurine Methyltransferase, and Histamine N-MethyltransferaseAnnual Review of Pharmacology and Toxicology, 1999
- Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemiaThe Journal of Pediatrics, 1991
- The Purine Path to ChemotherapyScience, 1989